Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intellect Neurosciences has entered into a license agreement with Wyeth and Elan Pharma International regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease.
Subscribe to our email newsletter
Under the terms of the agreement, Wyeth and Elan may pay Intellect potential future milestone payments and royalties based on sales of potential products, if it is determined that they are covered by patents that issue from Intellect’s patent applications.
Dr Chain, Intellect’s chairman and CEO, said: “We are delighted to enter into this licensing agreement, which provides Intellect a share in the future success of potential Wyeth and Elan products while we continue to develop our proprietary monoclonal antibodies for the treatment of Alzheimer’s disease.”